Last reviewed · How we verify
KHK4563
At a glance
| Generic name | KHK4563 |
|---|---|
| Sponsor | Kyowa Kirin Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis (PHASE2)
- A Phase IIa Study of KHK4563 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KHK4563 CI brief — competitive landscape report
- KHK4563 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI